Mutant KRas is preferentially enriched in EVs, concurrently with EGFR, RAP1, SRC, LYN, integrins, cortactin, and p120 catenin; promotes anchorage independent growth of colon cancer cells with wild type KRAS. Here, LYN is linked to colonic neoplasm.